Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported financial results for the second quarter after the market close on Monday. Here’s a rundown of the report.

Benzinga

Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings

What if a biotech company could flip its financial narrative from loss to profit in just a year? Twist Bioscience Corporation (NASDAQ:TWST) has done just that, reporting a surprising third-quarter income that defied analysts’ expectations

Benzinga

Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company announced positive topline results from its Phase 2 RADIANT study evaluating vormatrigine in patients with focal onset seizures and generalized epilepsy.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide

TG Therapeutics Inc. (NASDAQ:TGTX) stock is trading lower on Monday after the company reported worse-than-expected second-quarter 2025 earnings.

Benzinga

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

BioNTech SE (NASDAQ:BNTX) reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.

Benzinga

Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

Shares of CommScope Holding Company, Inc. (NASDAQ:COMM) rose sharply in pre-market trading.

Benzinga

Biogaran sale talks renew fears over foreign control of French pharma

France’s top generic drug maker, Biogaran, could soon be sold to a British investment fund, raising new fears about the country’s control over vital medicines.

Radio France Internationale

Read news from The Economist, FT, and more,
with one subscription

Avantor Q2 Feels The Impact From Bioprocessing Shortfalls, Customer Headwinds, Continued Margin Pressure

Avantor Inc. (NYSE:AVTR) stock is trading lower on Friday after the company reported worse-than-expected second-quarter 2025 adjusted EPS.

Benzinga

Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector

Shares of Novavax Inc (NASDAQ:NVAX) are trading lower Friday morning, appearing to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna Inc (NASDAQ:MRNA) reported disappointing second-quarter financial results and cut its full-year forecast.

Benzinga

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57.

Benzinga

Weight loss drugs could soon be used to treat these seven other health conditions

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success

The Independent UK

Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'

President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.

Benzinga

Hims & Hers Stock Up, Nearing All-Time High As Weight-Loss Giants Stumble

Shares of telehealth company Hims Hers Health Inc (NYSE:HIMS) are up Thursday afternoon, and at one point, approached a new all-time high. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.

Benzinga

Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount

With investors concerned about overall economic stability amid the Trump administration's tariff impact, they're not in a particularly generous mood. That may be the lesson learned the hard way by global pharmaceutical giant Sanofi SA (NASDAQ:SNY). Despite delivering an earnings report that offered an encouraging view, it wasn't a perfect…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) continue to outperform market expectations. Amid a backdrop of growing demand for innovative treatments, Alnylam’s recent performance highlights the company’s strong position in the competitive landscape.

Benzinga

Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06.

Benzinga

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23.

Benzinga

Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion

Bristol Myers Squibb Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 billion, almost flat year over year.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales

Sanofi SA (NASDAQ:SNY) reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.

Benzinga

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a notable 30.4% year-over-year increase.

Benzinga

Quantum BioPharma Shares' Rollercoaster Day: What's Going On?

Shares of Quantum BioPharma Ltd (NASDAQ:QNTM) started Wednesday with a surge before dropping, then heading back up slightly, despite a lack of company-specific news for the session. The biopharmaceutical company last week announced it had purchased 2,000 shares of GameStop Corp (NYSE:GME) as a strategic investment for its balance sheet.…

Benzinga

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) reported second-quarter adjusted earnings of 85 cents on Wednesday. The company reported an adjusted loss of $35 million a year ago.

Benzinga

Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a mixed performance amid continued shifts in its portfolio strategy.

Benzinga

Novo Nordisk Stock Hits New 52-Week Low Amid Profit Warning: What Investors Need To Know

Shares of Novo Nordisk A/S (NYSE:NVO) are trading lower Wednesday morning, extending a dramatic sell-off from Tuesday’s session. Here’s what investors need to know.

Benzinga

GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 guidance.

1 … 17 18 19 20

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.